Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
04:30pm, Monday, 08'th Jun 2026
RAHWAY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
01:04pm, Monday, 08'th Jun 2026
Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming dec
Baron Discovery Fund Q1 2026: Who Moved The Needle
01:35am, Monday, 08'th Jun 2026
In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. A
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
06:19pm, Friday, 05'th Jun 2026
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
03:03pm, Friday, 05'th Jun 2026
Assembly Biosciences NASDAQ: ASMB is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
03:00am, Friday, 05'th Jun 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Access--Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV preventio
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
04:15pm, Thursday, 04'th Jun 2026
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful complet
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
04:15pm, Thursday, 04'th Jun 2026
Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
12:55pm, Thursday, 04'th Jun 2026
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
11:16am, Thursday, 04'th Jun 2026
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
GILD Reports Positive Results From Late-Stage Liver Disease Study
12:21pm, Wednesday, 03'rd Jun 2026
Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
10:00am, Wednesday, 03'rd Jun 2026
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
01:47pm, Tuesday, 02'nd Jun 2026
Gilead Sciences, Inc. (NASDAQ) on Tuesday released results from the Phase 3 IDEAL study in people with primary biliary cholangitis (PBC).
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatmen
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
10:54am, Friday, 29'th May 2026
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
